Carbidopa

• Description:

  Carbidopa ((S) - (-) -Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth[1][2].

• Product Name Alternative:

  (S) - (-) -Carbidopa

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Aryl Hydrocarbon Receptor

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Carbidopa.html

• Purity:

  99.84

• Solubility:

  DMSO : 10 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles:

  OC1=C(O)C=CC(CC(NN)(C(O)=O)C)=C1

• Molecular Formula:

  C10H14N2O4

• Molecular Weight:

  226.23

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM) . Biochem J. 2017;474 (22) :3763-3765. Published 2017 Nov 6.|[2]Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43 (12) :587-591.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [28860-95-9]